Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Viridian Therapeutics Il CEO è Steve Mahoney, nominato in Oct2023, e ha un mandato di 1.08 anni. la retribuzione annua totale è $ 13.02M, composta da 0.9% di stipendio e 99.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.027% delle azioni della società, per un valore di € 411.94K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.1 anni e 4.1 anni.

Informazioni chiave

Steve Mahoney

Amministratore delegato

US$13.0m

Compenso totale

Percentuale dello stipendio del CEO	0.9%
Mandato del CEO	1.1yrs
Proprietà del CEO	0.03%
Durata media del management	1.1yrs
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Mahoney rispetto agli utili di Viridian Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$257m
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 13.02M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.64M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Steve con le performance aziendali.

AMMINISTRATORE DELEGATO

Steve Mahoney (53 yo)

1.1yrs

Mandato

US$13,022,654

Compensazione

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.027% € 411.9k
Seth Harmon	Senior VP of Finance and Accounting	1.2yrs	US$6.67m	0.0013% € 19.2k
Thomas Beetham	Chief Operating Officer	1.1yrs	US$5.17m	0.0076% € 115.4k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Vahe Bedian	Co-Founder & Scientific Advisor	no data	Nessun dato	Nessun dato
Jennifer Tousignant	Chief Legal Officer	less than a year	Nessun dato	Nessun dato
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato
Melissa Manno	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Anthony Casciano	Chief Commercial Officer	1.6yrs	Nessun dato	Nessun dato
Thomas Ciulla	Chief Medical Officer	1.8yrs	Nessun dato	0.00096% € 14.6k

1.1yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di 1S1 non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.027% € 411.9k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Arlene Morris	Independent Director	6.8yrs	US$477.83k	0% € 0
Victor Ambros	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Stefanie Dimmeler	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Jeffery Molkentin	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Eva van Rooij	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Tomas Kiselak	Independent Chairperson of Board	4.1yrs	US$503.83k	0% € 0
Jennifer Moses	Independent Director	3.3yrs	US$467.83k	0% € 0
Peter Harwin	Independent Director	4.1yrs	US$471.83k	0% € 0

4.1yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1S1 sono considerati esperti (durata media dell'incarico 4.1 anni).

Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CEO, President & Director recently bought €447k worth of stock

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Recent updates

Third quarter 2024 earnings released: US$1.16 loss per share (vs US$1.09 loss in 3Q 2023)

CEO, President & Director recently bought €447k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

First half 2024 earnings released: US$1.82 loss per share (vs US$2.88 loss in 1H 2023)

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought €92k worth of stock

President recently bought €149k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

First quarter 2022 earnings released: US$0.98 loss per share (vs US$2.91 loss in 1Q 2021)

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$2.22 loss per share (vs US$1.82 loss in 2Q 2020)

Independent Director Joseph Turner has left the company

Independent Chairman of the Board Jeffrey Hatfield has left the company

CFO, Secretary & Treasurer has left the company

First quarter 2021 earnings released: US$2.91 loss per share (vs US$2.65 loss in 1Q 2020)

Full year 2020 earnings released: US$31.13 loss per share (vs US$20.04 loss in FY 2019)

New 90-day low: €12.68

Viridian Therapeutics, Inc. Appoints Jonathan Violin, as Chief Executive Officer

miRagen Therapeutics, Inc. Announces Executive Changes

New 90-day high: €18.14

Miragen Therapeutics, Inc. Enters into License Agreement with Xencor for Use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Miragen Therapeutics, Inc. Announces Diana Escolar, M.D. to Resign as the Chief Medical Officer of the Company, Effective as of January 1, 2021

Revenue misses expectations

New 90-day high: €1.04

Miragen Therapeutics, Inc. (NasdaqCM:MGEN) acquired Viridian Therapeutics, Inc. for approximately $110 million.

Miragen Therapeutics, Inc. Announces Management Changes

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato